This cluster is routine and non-informative. All sales are at-market following option exercises, consistent with diversification. No C-suite selling, no above-market sales, no material dollar amount relative to market cap. Monitor next 10-Q for any fundamental changes, but no bearish read-through from this activity.
LGND drugs
LGND drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 18 $274.88entry
- T+1 · 5mo ago −4.62%α −4.31% · $262.17
- T+5 · 5mo ago +7.65%α +9.32% · $295.92
- T+20 · 4mo ago +7.85%α +7.31% · $296.45
- T+60 · 2mo ago +2.10%α +0.21% · $280.65
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Four LGND directors sold shares in a cluster totaling ~$2.5M in open-market sales following option exercises. The sales are all at-market, not above-market, and follow routine derivative exercises, consistent with tax-motivated diversification rather than a bearish signal.
Key Financial Metrics
Key Facts
- Four directors sold shares totaling ~$2.5M in open-market sales over a 7-day window
- All sales were preceded by option exercises at $0 or below-market strike prices, indicating tax-motivated sales
- Total cluster value is ~0.05% of LGND's $5.3B market cap, well below the 0.1% materiality threshold
- No C-suite executives (CEO/CFO) participated in the cluster, only directors
- LGND has 93% analyst bullish consensus and strong institutional support (BlackRock $591M, Vanguard $220M)
Financial Impact
~$2.5M total open-market sales, ~0.05% of $5.3B market cap
Risk Factors
- No material risk identified from this cluster, routine director-level diversification
- LGND's historical insider selling pattern (5 sells in 30d totaling $2.6M) is consistent with normal vesting
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-LGND-1781786377510 |
Track record
29 reports on LGND
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +38.85% at T+60 after the Apr 14, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $305.74 Now $301.71 −1.32% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $306.47 Now $301.71 −1.55% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $316.27 Now $301.71 −4.60% settles Feb 10
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $316.83 Now $301.71 −4.77% settles Feb 9
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $314.16 Now $301.71 −3.96% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $314.15 Now $301.71 −3.96% settles Feb 5
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers